Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme

Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 377-386

  Shen, Liangfang ^a   Zhou, Qin ^a   Wang, Ying ^a   Liao, Weihua ^a   Chen, Yan ^a   Xu, Zhijie ^b   Yang, Lifang ^a,b   Sun, Lun Quan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNAZYME; DT18; GADOLINIUM PENTETATE; MATRIGEL; MESSENGER RNA; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CANCER INHIBITION; CELL PROLIFERATION; CORNEA NEOVASCULARIZATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO SELECTION; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOUSE; NASOPHARYNX CARCINOMA; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DNA, CATALYTIC; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NASOPHARYNGEAL NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892608087     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00090     Document Type: Article

References (34)

1. Chung AS, Ferrara N. (2011) Developmental and pathological angiogenesis. Annual Review of Cell and Developmental Biology. 27:563-84.
2. Adams RH, Alitalo K. (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8:464-78.
3. Augustin HG, Koh GY, Thurston G, Alitalo K. (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 10:165-77.
4. Potente M, Gerhardt H, Carmeliet P. (2011) Basic and therapeutic aspects of angiogenesis. Cell. 146:873-87.
5. Carmeliet P, Jain RK. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298-307.
6. Friesel RE, Maciag T. (1995) Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. 9:919-25.
7. Gerber HP, Condorelli F, Park J, Ferrara N. (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes: Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272:23659-67.
8. Carmeliet P, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:575-83.
9. Cherrington JM, Strawn LM, Shawver LK. (2000) New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res. 79:1-38.
10. Ferrara N. (1997) The Role of Vascular Endothelial Growth Factor in the Regulation of Blood Vessel Growth. In: Tumour Angiogenesis. Bicknell R, Lewis CE, Ferrara N (eds.) Oxford University Press, New York, pp. 185-98.
11. Ellis LM, Takahashi Y, Liu W, Shaheen RM. (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist. 5 Suppl 1:11-15.
12. Ivy SP, Wick JY, Kaufman BM. (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 6:569-79.
13. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964-8.
14. Chen CT, Hung MC. (2013) Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. Am. J. Transl. Res. 5:393-403.
15. Santoro SW, Joyce GF. (1997) A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U. S. A. 94:4262-6.
16. Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. (2000) Catalytic nucleic acids: from lab to applications. Pharmacol. Rev. 52:325-47.
17. Rossi JJ. (2012) Resurrecting DNAzymes as sequence-specific therapeutics. Sci. Transl. Med. 4:139fs120.
18. Bhindi R, et al. (2007) Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based genesilencing strategies. Am. J. Pathol. 171:1079-88.
19. Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun LQ. (1999) Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol. 17:480-6.
20. Santiago FS, et al. (1999) New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat. Med. 5:1264-9.
21. Yang L, Lu Z, Ma X, Cao Y, Sun LQ. (2010) A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBV LMP-1 gene. Molecules. 15:6127-39.
22. Cai H, et al. (2012) DNAzyme targeting c-jun suppresses skin cancer growth. Sci. Transl. Med. 4:139ra182.
23. Cho EA, et al. (2013) Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 firstin-human trial (DISCOVER). Lancet. 381:1835-43.
24. Glaser R, et al. (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 86:9524-8.
25. Santoro SW, Joyce GF. (1998) Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry. 37:13330-42.
26. Cairns MJ, King A, Sun LQ. (2003) Optimisation of the 10-23 DNAzyme-substrate pairing interactions enhanced RNA cleavage activity at purinecytosine target sites. Nucleic Acids Res. 31:2883-9.
27. Parry TJ, et al. (1999) Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res. 27:2569-77.
28. Benimetskaya L, et al. (1998) Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides. Nucleic Acids Res. 26:5310-5317.
29. Cheng HL. (2007) Dynamic contrast-enhanced MRI in oncology drug development. Curr. Clin. Pharmacol. 2:111-22.
30. Agrawal S, et al. (1991) Pharmacokinetics biodistribution and stability of oligonucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U. S. A. 88:7595-9.
31. Bellou S, Pentheroudakis G, Murphy C, Fotsis T. (2013) Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett. 2:219-28.
32. Ratner M. (2004) Genentech discloses safety concerns over Avastin. Nat. Biotechnol. 22:1198.
33. Rahimi N. (2006) VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci. 11:818-29.
34. Zhang L, et al. (2002) Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res. 62:5463-9.